1. Scrip
  2. >>Therapy Areas
  3. >>Cardiovascular

SEAS remain rough for Vytorin

 
• By Alexandra Shimmings

Pressure onMerck/Schering-PloughPharmaceuticals Vytorin (ezetimibe plus simvastatin) is set to continue after the SEAS study showed that the combination hypolipaemic product failed to reach its primary endpoint in a new indication of aortic stenosis, and was associated with an increased risk of developing cancer.

Pressure onMerck/Schering-PloughPharmaceuticals Vytorin (ezetimibe plus simvastatin) is set to continue after the SEAS study showed that the combination hypolipaemic product failed to reach its primary endpoint in a new indication of aortic stenosis, and was associated with an increased risk of developing cancer.

Independent experts have stressed that the higher cancer rate appears due to the play of chance, and point out that...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

More from Therapy Areas

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.